MetaCap

Co-Diagnostics (CODX) vs Profusa (PFSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Profusa is the larger company by market cap ($1.8 million vs $1.4 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CODX-88.44%PFSA-78.44%
+17%-38%-93%
Oct 7, 20261 yearNov 20, 2026
CODX-88.44%PFSA-77.23%
+4%-44%-93%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CODX versus PFSA key metrics
MetricCODXPFSA
Share price$0.1295$0.3234
Market cap$1.36M$1.84M
1-day change-21.32%-6.40%
P/E ratio (TTM)—0.00
EPS (TTM)$-21.71$6,415.28
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$622.49K—
Revenue growth (YoY)-84.10%—
Net income (latest FY)$-46.90M$-35.82M
Gross margin64.28%—
Operating margin-8058.83%—
Net margin-7533.62%—
52-week high$13.54$1,515.00
52-week low$0.1276$0.31
Distance from 52-week high-99.04%-99.98%
Analyst consensusnone—
Avg. price target upside+2988.80%—
Average volume2.03M2.74M
Shares outstanding10.51M5.68M
Employees115—
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Co-Diagnostics

CODX stock →

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

Health Care · Medical/Dental Instruments · 115 employees

About Profusa

PFSA stock →

Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.

Health Care · Medical/Dental Instruments

CODX vs PFSA FAQ

Which is bigger, Co-Diagnostics or Profusa?

Profusa (PFSA) is larger, with a market capitalization of $1.84M compared with $1.36M for Co-Diagnostics (CODX).

Are Co-Diagnostics and Profusa in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons